This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bull of the Day: Salesforce.com (CRM)
by David Borun
This brand-new Dow component continues to beat the estimates and raise guidance.
Powerful Proof Anyone Can Invest for an Early Retirement - August 31, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Bayer Submits Application for Heart Failure Drug in China
by Zacks Equity Research
Bayer (BAYRY) submits a regulatory application seeking approval for vericiguat to treat patients with symptomatic chronic heart failure in China.
Gilead's Veklury Gets FDA Nod for Expanded Use in Coronavirus
by Zacks Equity Research
Gilead's (GILD) Veklury can now be used to treat all hospitalized patients with COVID-19, in addition to severe COVID-19.
Dow Turns Green YTD in Old Format: What Will the Revamp Unfold?
by Nalak Das
The revamp is likely to make the Dow more market-friendly and reflect investors' sentiments more accurately.
More new Highs and the Best August in 36 Years
by David Borun
A change in Fed policy helps
Biotech Industry Near-Term Outlook Modest Amid Coronavirus
by Zacks Equity Research
With the coronavirus outbreak refusing to subside anytime soon, biotech companies gain focus as they race against time to evaluate every possible therapy to break the chain.
Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.
Why Is Amgen (AMGN) Up 0.5% Since Last Earnings Report?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Signs That Your Trading Will Ruin Your Retirement - August 27, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Dow Jones ETF in Focus on Index Shake-Up
by Sweta Killa
Given the tech sector dominance, many Wall Street analysts believe the post-reshuffle Dow Jones could struggle to catch up with the S&P 500 and the Nasdaq Composite, which have been hitting new highs.
Apple Stock Split Prompts Significant Changes in the Dow
by David Borun
The world's most widely referenced stock market index will soon swap out 10% of its holdings
AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis
by Zacks Equity Research
AbbVie (ABBV) files an application to the FDA, seeking its nod for a new indication of Rinvoq, which is active ankylosing spondylitis. The drug is already marketed to treat rheumatoid arthritis.
Stock Market News for Aug 26, 2020
by Zacks Equity Research
The S&P 500 and the Nasdaq hit an all-time high on Tuesday, while the Dow declined amid mixed economic news and decline in heavy weights like Exxon Mobil and Boeing.
Apple Stock Split Prompts Dow Reshuffle: Who's In, Who's Out?
by Tirthankar Chakraborty
Apple's stock split reduced its weight in the Dow, prompting a shake-up in the blue-chip index, with salesforce.com, Amgen and Honeywell taking Exxon, Raytheon and Pfizer's spot.
Stock Futures Mostly Higher on Trade Talks, Dow's Shake-Up in Focus
by Zacks Equity Research
This morning, Treasury Secretary Steven Mnuchin and Trade Representative Robert Lighthizer had a telephonic discussion with Chinese vice premier Liu He.
Merck's Keytruda Gets Approval for Esophageal Cancer in Japan
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval in Japan as second-line treatment for esophageal squamous cell carcinoma. A new dosing regimen also receives approval in the country.
Strong Market Momentum Continues
by Zacks Equity Research
Strong Market Momentum Continues
Amgen's New Kyprolis Combo Gets FDA Nod for Multiple Myeloma
by Zacks Equity Research
Amgen's (AMGN) Kyprolis gets FDA approval for label expansion as second to fourth-line treatment for relapsed/refractory multiple myeloma in combination with J&J's Darzalex and dexamethasone.
Simple Secrets Anyone Can Use to Reach Early Retirement - August 21, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Merck's Keytruda Positive in First-Line Esophageal Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda improves overall survival and progression-free survival compared to current standard of care in first-line metastatic esophageal cancer patients.
The Extreme Risks of Trading Your Own Retirement Assets - August 19, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
The Zacks Analyst Blog Highlights: Amazon, Amgen, TOTAL, Vertex Pharmaceuticals and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Amgen, TOTAL, Vertex Pharmaceuticals and FedEx
Roche Gets FDA Nod for Nervous System Disorder Drug Enspryng
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for NMOSD drug under the brand name, Enspryng.
Top Research Reports for Amazon, Amgen & TOTAL
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), Amgen (AMGN) and TOTAL (TOT).